

Form 4: IRB Approval Form
Identification and Certification of Research
Projects Involving Human Subjects

UAB's Institutional Review Boards for Human Use (IRBs) have an approved Federalwide Assurance with the Office for Human Research Protections (OHRP). The Assurance number is FWA00005960 and it expires on January 24, 2017. The UAB IRBs are also in compliance with 21 CFR Parts 50 and 56.

Principal Investigator: MALIK, TALHA A

Co-Investigator(s):

Protocol Number: **X081224003**

Protocol Title: *Characteristics, Complications, Prognostic Predictors, Treatment and Outcome of all Patients with IBD Seen at UAB*

The IRB reviewed and approved the above named project on 10/17/16. The review was conducted in accordance with UAB's Assurance of Compliance approved by the Department of Health and Human Services. This Project will be subject to Annual continuing review as provided in that Assurance.


This project received EXPEDITED review.

IRB Approval Date: 10/17/16

Date IRB Approval Issued: 10-17-16

IRB Approval No Longer Valid On: 10-17-17

HIPAA Waiver Approved?: Yes



Expedited Reviewer
Member - Institutional Review Board
for Human Use (IRB)

Investigators please note:

The IRB approved consent form used in the study must contain the IRB approval date and expiration date.

IRB approval is given for one year unless otherwise noted. For projects subject to annual review research activities may not continue past the one year anniversary of the IRB approval date.

Any modifications in the study methodology, protocol and/or consent form must be submitted for review and approval to the IRB prior to implementation.

Adverse Events and/or unanticipated risks to subjects or others at UAB or other participating institutions must be reported promptly to the IRB.

**UAB IRB Approval of
Waiver of Informed Consent and/or Waiver of Patient Authorization**

- ☒ **Approval of Waiver of Informed Consent to Participate in Research.** The IRB reviewed the proposed research and granted the request for waiver of informed consent to participate in research, based on the following findings:

1. The research involves no more than minimal risk to the subjects.
2. The research cannot practicably be carried out without the waiver.
3. The waiver will not adversely affect the rights and welfare of the subjects.
4. When appropriate, the subjects will be provided with additional pertinent information after participation.

Check one: ☒ **and** Waiver of Authorization (below)
☐ **or** Waiver of Authorization (below)
☐ Waiver of Authorization not applicable

- ☒ **Approval of Waiver of Patient Authorization to Use PHI in Research.** The IRB reviewed the proposed research and granted the request for waiver of patient authorization to use PHI in research, based on the following findings:

1. The use/disclosure of PHI involves no more than minimal risk to the privacy of individuals
 - i. There is an adequate plan to protect the identifiers from improper use and disclosure.
 - ii. There is an adequate plan to destroy the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or research justification for retaining the identifiers or such retention that is otherwise required by law.
 - iii. There is an assurance that the PHI will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of PHI would be permitted.
2. The research cannot practicably be conducted without the waiver or alteration.
3. The research cannot practicably be conducted without access to and use of the PHI.

—OR—

☐ **Full Review**

The IRB reviewed the proposed research at a **convened meeting** at which a majority of the IRB was present, including one member who is not affiliated with any entity conducting or sponsoring the research, and not related to any person who is affiliated with any of such entities. The waiver of authorization was approved by the majority of the IRB members present at the meeting.

Date of Meeting _____

Signature of Chair, Vice-Chair or Designee _____

Date _____

☒ **Expedited Review**

The IRB used an **expedited review procedure** because the research involves no more than minimal risk to the privacy of the individuals who are the subject of the PHI for which use or disclosure is being sought. The review and approval of the waiver of authorization were carried out by the Chair of the IRB, or by one of the Vice-Chairs of the IRB as designated by the Chair of the IRB.

10/17/16
Date of Expedited Review

Talha Malik
Signature of Chair, Vice-Chair or Designee

10/17/16
Date